TCTMD’s Top 10 Most Popular Stories for May 2024

Most of our top stories this month stemmed from the EuroPCR and European Society of Cardiology (ESC) Heart Failure meetings, with several notable exceptions. The results for the FLOW trial of semaglutide in patients with diabetes and chronic kidney disease narrowly missed the top spot this month, while a feature story digging into the expected impact of the DanGer Shock trial of a percutaneous left ventricular assist device took third place.

1. Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Interventionalists at EuroPCR seemed stunned by these results—a clear win for PCI/TAVI—but surgeons argued the devil is in the details.

2. FLOW: Semaglutide Scores Big in Diabetic Patients With CKD

In addition to a 24% reduction in major kidney disease events, the semaglutide group had 18% less MACE at 3 years versus placebo.

3. After DanGer Shock’s Win in AMICS for Impella: What’s Next?

Interventionalists say it’s now time to make a dent in the complication rate, whether by strict protocols or smaller devices.

4. Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

The first trial to test shortened DAPT in coronary DCBs, REC-CAGEFREE II builds upon the evidence available for DES PCI.

5. SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

According to Stephen Greene, these results underscore the value of optimizing GDMT in patients with HF before moving to invasive therapy.

6. ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

A few simple questions that gauge whether symptoms are—or aren’t—typical could provide valuable insights to drive care, a new analysis shows.

7. Remote Monitoring in Real-world HF Cuts All-Cause Mortality: TELESAT-HF

These data, presented at the ESC’s Heart Failure congress, are observational but suggest that basic remote monitoring of weight and symptoms can cut patient risk.

8. Myval Matches Contemporary TAVI at 30 Days, but Do More Sizes Matter?

The Indian-made valve, available in nine sizes, still needs to deliver on outcomes in a randomized trial, experts agreed.

9. ShortCut Leaflet Splitter Proves Safe, May Streamline Valve-in-Valve TAVI

The dedicated device can lacerate bioprosthetic leaflets poised to cause coronary obstruction—and does it more quickly and safely than more cumbersome workarounds, like BASILICA.

10. Go Beyond Angiography in CCS to Pinpoint the Problem, Urges AID-ANGIO

A hierarchical strategy of intracoronary testing takes just minutes, researchers say, and can provide clarity on diagnoses, like INOCA, that are too often overlooked with angiograms alone.

*   *   *

For all of our coverage of EuroPCR as well as ESC-HF, SCAI, HRS, and ESOC, please visit our conference hub. Find in-depth video interviews for AID-ANGIO, the TCW trial, REC-CAGEFREE II, and NOTION-2 in our video center.